Injectable Stem Cell Hydrogel Beads for Higher Engraftment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing stem cell therapeutic agents result in low engraftment rates and cell loss due to proteolytic enzyme treatment, difficulty in maintaining intercellular bonding, and inefficient cryopreservation methods that can damage cells and require complex removal of cryopreservation solutions.
Innovation Solution
A method of preparing mesenchymal stem cell-hydrogel compositions in a consistent bead form with diameters of 0.1 to 5 mm, using fibrin glue, which allows for easy syringe filling, cryopreservation, and simple removal of cryopreservation solutions, without proteolytic enzyme treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If proteolytic enzymes are used to treat isolated cells, then cells can be separated and collected, but intercellular bonding and basement membrane proteins are damaged and cell membranes are harmed
Solution Approach 1:
The patent extracts and removes proteolytic enzymes from the cell isolation process entirely. Instead of using trypsin or dispase to detach cells, the invention employs mechanical dissociation methods and gentle chemical agents that do not compromise cell membrane integrity, thereby eliminating the harmful effects while maintaining cell collection capability
Solution Approach 2:
The patent introduces alternative agents and methods as intermediaries between the cell and the culture vessel. These include mechanical agitation, enzymatic-free dissociation buffers, and controlled shear stress applications that enable cell separation without direct proteolytic attack on cell membranes and extracellular matrix proteins
2Ease of operation
If single cells are transplanted to a diseased site, then injection is simple, but cells are released through diffusion and absorption resulting in low engraftment rates
Solution Approach 1:
The patent merges multiple cells into clustered structures or aggregates before injection. These cell clusters maintain intercellular bonding and basement membrane proteins, creating a more stable therapeutic unit that resists diffusion and absorption in the target tissue, thereby improving engraftment rates while remaining injectable
Solution Approach 2:
The patent performs preliminary actions to prepare cell clusters with enhanced structural integrity before injection. This includes pre-forming three-dimensional cell aggregates, reinforcing cell-cell adhesion molecules, and protecting basement membrane proteins through gentle handling protocols that ensure clusters maintain their structure upon injection and in the target tissue
3Productivity
If mesenchymal stem cells are separated into single cells, then cell suspension is achieved, but cells are killed within 6 to 24 hours due to their adhesive nature
Solution Approach 1:
The patent applies local quality by creating heterogeneous cell structures with varying degrees of aggregation. Some regions contain tightly bound cell clusters that maintain adhesive interactions and survival signals, while other regions provide suspension characteristics for uniform distribution. This spatial variation in cell organization allows simultaneous achievement of suspension uniformity and cell survival
Solution Approach 2:
The patent employs beforehand cushioning by providing protective microenvironments within cell clusters that shield adhesive cells from the stresses of suspension and injection. These clusters create protected niches that maintain cell viability through preserved cell-cell contact and reduced exposure to harmful mechanical and chemical stresses during handling and transplantation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method ensures high engraftment rates by maintaining stem cells on hydrogel scaffolds, preserves cell membrane integrity, and facilitates easy removal of cryopreservation solutions, enhancing the paracrine effect and therapeutic efficacy of mesenchymal stem cells.
Implementation Method 1
the stem cells are gradually released as hydrogel is degraded
Implementation Method 2
a method of preparing stem cell-hydrogel in a constant form with a diameter of 5 mm or less to be developed into a formulation that can be easily filled into a syringe, cryopreserved, and immediately thawed to be used
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
The present invention relates to a composition containing injectable mesenchymal stem cell-hydrogel and a method of preparing the same. Specifically, in a mesenchymal stem cell-hydrogel composition for injection prepared by a method of the present invention, since stem cells are attached to scaffolds in hydrogel beads, the stem cells are not easily lost or killed after the injection, and thus there is an advantage that an engraftment rate increases since the paracrine effect of the stem cells is continuously exhibited, and the stem cells are gradually released as hydrogel is degraded. In addition, the present invention has an advantage that healthy cells can be used without damages in cell membranes since injection formulation can be prepared without a treatment with proteolytic enzymes, and also a cryopreservation solution is easily removed from the mesenchymal stem cell-hydrogel beads even after freezing and thawing.